00718-A: Ras Mutations in Canine Lymphoid and Myeloid Leukemias
Grant Status: Closed
Grant Amount: $10,800
Laura Blackwood, PhD; University of Liverpool
March 1, 2006 - February 28, 2007
Sponsor(s):
Breed(s): -All Dogs
Research Program Area: Oncology
Donate to Support this Research Program Area
Abstract
Ras is the most frequently mutated oncogene in human cancer, and ras mutations are seen in up to 20 percent of patients with acute lymphoid leukemia, and 20-44 percent of patients with acute myeloid leukaemia. These mutations provide a proliferative signal by activation of the RTK/ras signalling pathways, and in human patients the presence or absence of these mutations is associated with prognosis and chemosensitivity. The molecular genetics of canine leukemia are undefined. We hypothesize that ras mutations are likely to occur in canine leukemias and our objective is to identify and characterize these mutations and determine their frequency and significance.Publication(s)
Usher, S. G., Radford, A. D., Villiers, E. J., & Blackwood, L. (2009). RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. Experimental Hematology, 37(1), 65–77. https://doi.org/10.1016/j.exphem.2008.09.005
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
